Adult height and health-related quality of life after growth hormone therapy in small for gestational age subjects.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

To estimate health-related quality of life (HRQoL) in non-growth hormone deficient (GHD) small for gestational age (SGA) children before and after growth hormone (GH) treatment to adult height (AH).

Why It Was Studied

The analysis assumes HRQoL can be mapped onto height SDS.

Who Took Part

PubMed indexes the participants as young children, children and teenagers, both men and women.

Following an initial 2-year double-blind study period, patients entered a 2-year extension period followed by treatment to AH.

How the Study Was Run

The researchers set it up as a randomized, double-blind and multicenter study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

This was a multicentre, two-arm trial.

Height standard deviation score (SDS) before and after GH therapy was mapped onto estimated HRQoL scores up to AH.

What Was Measured

Topics PubMed links to this paper include Body Height, Human Growth Hormone, Infant, Small for Gestational Age, Quality of Life and Recombinant Proteins.

What This Means in Plain Language

The paper is a randomized, double-blind and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (Journal of medical economics), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.